Weekly Analysts’ Ratings Changes for AtriCure (ATRC)

AtriCure (NASDAQ: ATRC) recently received a number of ratings updates from brokerages and research firms:

• 7/28/2026 – AtriCure was upgraded by Weiss Ratings from “sell (e+)” to “sell (d+)”.
• 7/28/2026 – AtriCure had its price target lowered by UBS Group AG from $55.00 to $50.00. They now have a “buy” rating on the stock.
• 7/28/2026 – AtriCure had its price target lowered by UBS Group AG from $55.00 to $50.00. They now have a “buy” rating on the stock.
• 7/24/2026 – AtriCure was upgraded by Zacks Research from “hold” to “strong-buy”.
• 7/21/2026 – AtriCure was given a new $52.00 price target by Raymond James Financial, Inc..
• 7/21/2026 – AtriCure had its “market outperform” rating reaffirmed by Citigroup Inc..

Insider Transactions at AtriCure

In other news, Director Sven Wehrwein sold 25,000 shares of the company’s stock in a transaction dated Tuesday, July 28th. The shares were sold at an average price of $37.84, for a total transaction of $946,000.00. Following the transaction, the director owned 40,518 shares in the company, valued at approximately $1,533,201.12. This represents a 38.16% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Karen Prange sold 3,000 shares of the firm’s stock in a transaction on Wednesday, May 20th. The shares were sold at an average price of $28.65, for a total transaction of $85,950.00. Following the completion of the transaction, the director directly owned 26,373 shares in the company, valued at $755,586.45. This trade represents a 10.21% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 40,182 shares of company stock valued at $1,505,092. 4.00% of the stock is currently owned by company insiders.

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.